ClinicalTrials.gg
RecruitingNCT06297278BRAINSUpdated Oct 21, 2026

Exercise Facilitation of Adolescent Fear Extinction, Frontolimbic Circuitry, and Endocannabinoids

An interventional study of Moderate Intensity Exercise in Adolescence, sponsored by Wayne State University. Recruiting at 1 site in United States. Open to participants aged 14 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Primary conditionAnxiety Disorders(the registry's first term)UnverifiedIs this wrong?The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Wayne State University · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
174
Allocation
Randomized
Ages
14 Years to 17 Years
Sex
All
01

Study summary

Anxiety disorders commonly begin during adolescence, and are characterized by deficits in the ability to inhibit or extinguish pathological fear. Recent research has provided new understanding of how fear is learned and can be regulated in the adolescent brain, and how the endocannabinoid system shapes these processes; however, these advances have not yet translated into improved therapeutic outcomes for adolescents with anxiety. This study will test whether a behavioral intervention, acute exercise, can help to improve fear regulation by enhancing brain activity and endocannabinoid signaling. This line of research may ultimately lead to more effect treatments for adolescent anxiety, and to new preventive strategies for at-risk youth.

02

Conditions studied

  • Adolescence

Browse trials for

Keywords

  • anxiety
  • exercise
  • fear
03

In context

Anxiety Disorders Unverified

7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.

This study's planned enrollment of 174 is above the median of 80 across 6,103 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Wayne State University is the lead sponsor of 231 studies on the registry; 36 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 4 (24%) have results posted.

Compared within Anxiety Disorders, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
14 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated form
  2. Stated willingness to comply with all study procedures and available for the duration of the study
  3. 14-17 years of age upon enrollment
  4. Right-handed
  5. In good general health as evidenced by medical history
  6. Adolescent and parent/guardian are English-speaking, as study assessments are in English
  7. Availability of a parent or legal guardian who is willing to provide consent and attend all study visits

Exclusion criteria

Exclusion Criteria:

  1. Traumatic brain injury with ongoing symptoms
  2. Sensory (e.g., hearing) or physical (e.g., motor, balance) impairment or significant developmental delay
  3. MRI participants: MRI (e.g., braces, implants, claustrophobia)
  4. Any condition that would contraindicate blood draws (e.g., hemophilia, sickle cell)
  5. Past or current diagnosis or presence of likely neurological disorder (e.g., epilepsy), psychotic disorder (e.g., schizophrenia, schizoaffective disorder), or bipolar disorder
  6. Severe/unstable medical condition (e.g., diabetes, rheumatoid arthritis)
  7. Current (past 1-month) use of cannabis or cannabinoid products including CBD unless willing to stop for at least 4 weeks prior to entering the study
  8. Currently pregnant, lactating, or positive pregnancy test at screening visit
  9. Current homicidal thoughts or suicide attempt in the past year
  10. Current suicidal thoughts requiring immediate intervention
  11. Concurrent use (past 6 weeks) of oral
  12. Diagnosed or probable substance use disorder (past 1-month)
  13. Positive drug test at baseline visit (e.g., THC, cocaine)
  14. Moderate/severe drug or alcohol use in the past 8 weeks
  15. Current or recent (past 1-month) COVID-19 diagnosis or febrile illness
  16. Treatment with drug or intervention (past 1-month)
  17. Current smoker, vaper, or tobacco or nicotine use (past 1-month)
  18. Ongoing exposure to abuse
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
174 participants (estimated)

Study arms

  • Experimental
    Moderate Intensity Exercise

    Behavioral: Moderate Intensity Exercise

  • No intervention
    Control (Coloring)

Interventions

  • BehavioralModerate Intensity Exercise

    Participants randomized to the active (moderate intensity) exercise condition will complete a 3-minute warm-up at low speed on a treadmill. Speed and incline will be increased in 3-minute increments until moderate-intensity exercise, defined as participants staying within a zone of 60-80% AAMHR with the target being to attain and maintain 70-75% AAMHR while briskly walking and/or jogging depending on current fitness status, is reached for a total of 30 min.

06

What researchers measure

Primary outcomes

  1. Skin Conductance Responding (SCR)

    To compare the effects of acute moderate-intensity exercise (vs. sedentary control) on extinction recall, the investigators will place three electrodes on participant's left hand to acquire SCR data using a BIOPAC MP160 Data Acquisition System (BIOPAC Systems, Inc.).

    Time frame: Throughout study completion (3 days)

  2. Unconditioned Stimulus (US) Expectancy Ratings

    US Expectancy Ratings will be measured during fear learning, extinction, and recall tasks

    Time frame: Throughout study completion (3 days)

  3. Fear extinction neural circuitry: Functional activation and coupling

    MRI eligible only: fMRI blood-oxygen-level-dependent (BOLD) response will be measured across the entire brain during a test of extinction recall. The investigators will focus on response in the hippocampus and ventromedial prefrontal cortex activation and coupling (gPPI) during recall (CS+E\>CS+U).

    Time frame: Neuroimaging will occur during the fear extinction recall phase on Day 3

  4. Endocannabinoid (eCB) Concentrations

    Plasma and saliva samples will be collected immediately before and after exercise or sedentary control condition. Samples will be analyzed using liquid chromatography-mass spectrometry to quantify concentrations of eCBs.

    Time frame: eCB concentrations will be measured in plasma and saliva immediately before and after the exercise or control condition on Day 2

Secondary outcomes

  1. Fear Ratings

    Fear ratings to each CS will be captured at the beginning, middle, and end of each phase, using a response pad and a 1-5 visual analog scale (1 = not scary at all, 5 = very scary).

    Time frame: Throughout study completion (3 days)

  2. Approach/Avoidance Behavior

    The investigators will quantify forward-to-backward response pad distance in virtual meters from the conditioned stimulus.

    Time frame: Throughout study completion (3 days)

  3. Amygdala response during extinction recall

    MRI Eligible Only: fMRI blood-oxygen-level-dependent (BOLD) response will be measured across the entire brain during a test of extinction recall. A secondary region of interest is amygdala response during recall (CS+E\>CS+U).

    Time frame: Neuroimaging will occur during the fear extinction recall phase on Day 3

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Apr 2028, 47 months after the start.

Of 3,871 non-industry interventional studies with no phase under Anxiety Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 47 months is above that.

Counting every sponsor, half of 3,976 studies reached it within 12 months; a quarter within 5 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2024
First posted
Mar 7, 2024
StartActual
May 17, 2024
Primary completionEst.
Apr 30, 2028
CompletionEst.
Apr 30, 2028
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date, oversight details and data sharing statement
1 update, last Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Minor edits only
    + 3 other changes: verification date, oversight details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06297278
Responsible party
Hilary Marusak (Assistant Professor, Wayne State University) — Principal investigator
First posted
Mar 7, 2024
Start date
May 17, 2024
Primary completion
Apr 30, 2028 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Oct 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion